Physician profile
Stephen Kb Chinn
NPI 1336245901
$3,384.25
in general payments reported to CMS, 2019-2025
10 companies · $448 in 2025
The $448 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $284 · 2021: $196 · 2022: $500 · 2023: $732 · 2024: $567 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $884.95 | 2019-2025 | Xtandi |
| Boston Scientific Corporation | $881.82 | 2021-2025 | Ams 700, General - Erectile Dysfunction, Tactra |
| Janssen Biotech, INC. | $356.71 | 2022-2024 | Erleada, Akeega |
| Pfizer INC. | $335.98 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $251.70 | 2023 | Orgovyx |
| Intuitive Surgical, INC. | $182.40 | 2019-2020 | |
| Neotract INC. | $144.10 | 2020 | |
| Photocure INC | $124.71 | 2019 | |
| Endo Pharmaceuticals INC. | $121.88 | 2023 | Xiaflex |
| Comsort, INC | $100.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.